MediciNova vs Mereo BioPharma Group
Mereo BioPharma Group reported revenue of $0 million in fiscal 2025, 1.2 times MediciNova's $0 million in fiscal 2025. MediciNova had an operating margin of -3242.5%, against -8021.4% at Mereo BioPharma Group. Free cash flow was −$10 million at MediciNova and −$31 million at Mereo BioPharma Group.
Side by side
| MediciNova | Mereo BioPharma Group | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $0M | $0M |
| Revenue growth | — | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −3,242.5% | −8,021.4% |
| Net margin | −2,928.8% | −8,375.6% |
| Free cash flow | −$10M | −$31M |
| Free cash flow margin | −2,395.4% | −6,198.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.0% | 7.8% |
| Last close | $1.27 | $0.28 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $1.7 million | — |
| Piotroski F-score | — | 4 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MediciNovaMereo BioPharma Group
Operating margin
Percent of revenue
MediciNovaMereo BioPharma Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MediciNovaMereo BioPharma Group
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the MediciNova and Mereo BioPharma Group pages.